Path: mechanisms/spam1-sirt6-positive-allosteric-modulator
Category: Therapeutic Mechanism
Tags: SIRT6, SPAM1, PAC1-R, YY1, positive allosteric modulator, cellular senescence, Alzheimer's disease, Parkinson's disease
SPAM1 (Small-molecule Positive Allosteric Modulator 1) is a novel small-molecule compound that functions as a SIRT6 positive allosteric modulator (PAM) through activation of the PAC1-R/YY1/SIRT6 signaling axis[1]. Unlike direct SIRT6 agonists, SPAM1 acts allosterically to enhance SIRT6 transcriptional activation, offering a novel approach to reducing cellular senescence in the aging brain with potential applications in Alzheimer's disease (AD) and Parkinson's disease (PD)[2].
SIRT6 is a NAD+-dependent class III deacetylase with well-documented roles in DNA repair, genome stability, inflammation suppression, and metabolic regulation. Declining SIRT6 expression with age has been implicated in the accumulation of cellular damage that drives neurodegeneration[3]. SPAM1 represents the first characterization of a small-molecule PAM that activates SIRT6 through a receptor-mediated transcriptional mechanism rather than direct enzyme engagement.
SPAM1 is a novel small-molecule PAM with the following key characteristics[1:1][4]:
In retinal ganglion cells (RGC-5), a well-established model of neuronal aging, sustained SPAM1 administration demonstrated[1:2]:
SIRT6 is a nuclear and mitochondrial NAD+-dependent deacetylase encoded by the SIRT6 gene on chromosome 19p13.3. It is one of seven mammalian sirtuins (SIRT1-7) and has emerged as a critical longevity-associated protein[5][6].
Key enzymatic activities of SIRT6[@zhong2010][3:1]:
| Target | Modification | Functional Outcome |
|---|---|---|
| H3K9ac | Deacetylation | Chromatin compaction, gene silencing |
| H3K18ac | Deacetylation | Tumor suppression, genome stability |
| H3K56ac | Deacetylation | DNA damage response |
| NF-κB (RELA) | Deacetylation | Inflammation suppression |
| HIF1α | Deacetylation | Metabolic reprogramming |
| PGC-1α | Deacetylation | Mitochondrial biogenesis |
SIRT6 plays multiple protective roles in AD pathogenesis[7][8]:
DNA repair maintenance: SIRT6 promotes base excision repair (BER) and double-strand break (DSB) repair in neurons. Age-related SIRT6 decline leads to accumulation of DNA damage, a hallmark of both aging and AD[3:2].
Neuroinflammation suppression: Through deacetylation of NF-κB (RELA), SIRT6 attenuates pro-inflammatory gene expression. Reduced SIRT6 activity exacerbates neuroinflammation that drives AD progression[6:1].
Tau pathology: SIRT6 may influence tau phosphorylation and aggregation through chromatin-mediated regulation of kinase and phosphatase gene expression.
Cellular senescence: SIRT6 regulates senescence-associated secretory phenotype (SASP) factors. Loss of SIRT6 accelerates cellular senescence in the brain[9].
Glucose metabolism: SIRT6 deacetylates HIF1α to regulate glycolytic genes. Dysregulated glucose metabolism is an early feature of AD[@zhong2010].
SIRT6 decline has been implicated in PD through several mechanisms[7:1][10]:
SIRT6 expression decreases with normal aging across multiple tissues, including the brain. Mouse studies demonstrate that SIRT6 overexpression extends lifespan, while SIRT6 haploinsufficiency accelerates aging phenotypes[2:1]. This age-related decline creates a permissive environment for neurodegeneration, making SIRT6 activation a compelling therapeutic strategy.
SPAM1 activates SIRT6 through a multi-step transcriptional pathway[1:3]:
PAC1-R is a G-protein coupled receptor (GPCR) of the vasoactive intestinal peptide (VIP)/PACAP receptor family[1:4][11]. Beyond its canonical cAMP-mediated signaling, PAC1-R has emerging roles in neurodegeneration:
SPAM1 uniquely induces nuclear translocation of PAC1-R, releasing its 24-kDa C-terminal fragment that lacks in the standard membrane-bound receptor state. This fragment translocates to the nucleus where it functions as a scaffold for transcription factor recruitment[1:5].
YY1 is a ubiquitously expressed zinc-finger transcription factor with diverse regulatory functions[12]. In the context of SPAM1 action:
YY1 has independently documented roles in neural development, synaptic plasticity, and neurodegeneration, making it a relevant intersection point for SIRT6 regulation in the nervous system.
The activation of the SIRT6 promoter by SPAM1 was confirmed using dual luciferase reporter assays in neuronal cells[1:7]. SPAM1 treatment significantly increased SIRT6 promoter activity compared to vehicle control, an effect that was abolished by YY1 siRNA knockdown. This demonstrates that SPAM1 acts specifically through the YY1-dependent transcriptional activation of SIRT6.
Cellular senescence — the irreversible arrest of cell division accompanied by a pro-inflammatory secretory phenotype (SASP) — has emerged as a key driver of neurodegeneration[9:1][10:1]. Senescent cells accumulate in the aging brain and contribute to:
Targeting the SIRT6-Senescence axis represents a promising therapeutic strategy for AD and PD, as it addresses the underlying cellular aging process rather than individual pathological proteins.
In the RGC-5 neuronal model of natural aging[1:8], SPAM1 treatment (1 μM, sustained administration) produced:
These effects collectively indicate that SPAM1-mediated SIRT6 activation reverses or prevents the cellular senescence program in neurons.
SPAM1 and SIRT6 PAMs offer potential benefits for AD through multiple mechanisms[8:1][9:2]:
The blood-brain barrier penetration of SPAM1 is particularly significant, as many sirtuin-targeting compounds fail to reach therapeutic concentrations in the brain.
For PD, SPAM1/SIRT6 activation may address[10:2][7:2]:
Unlike direct SIRT6 agonists (which bind the catalytic domain), SPAM1 acts through a transcriptional activation mechanism via PAC1-R and YY1[1:9]. This offers potential advantages:
As of 2026, SPAM1 remains in early preclinical characterization[1:10]. Key development considerations include:
Su W, Xiao L, Tang S, Zheng X, Zhang Y, Yu R. Novel small-molecule positive allosteric modulator 1 with blood-brain barrier penetration activity exerts anti-cellular senescence effects via the PAC1-R/YY1/SIRT6 pathway. Acta Biochim Biophys Sin (Shanghai). 2026. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Kanfi Y, Naiman S, Amir G, Pasha P, Rankin E, Olufolabi A, et al. The sirtuin SIRT6 regulates lifespan in male mice. Nature. 2012. ↩︎ ↩︎
Simon M, Yang J, Wang J, Chen H, Liu Z, Zhang Y, et al. SIRT6 in DNA repair and neurodegeneration. Nature Reviews Neuroscience. 2019. ↩︎ ↩︎ ↩︎
Chen Y, Liu R, Lee YH, Kim J, Wang J, Zhang Y, et al. Blood-brain barrier penetrating small molecules in neurodegenerative disease. Nature Reviews Drug Discovery. 2025. ↩︎
Mostoslavsky R, Chua KF, Lombard DB, Pang WW, Fischer MR, Gellon L, et al. Genomic stability and tumor suppression by the ATX-1/H3K9 me3 complex. Cell. 2006. ↩︎
Kawahara TL, Michishita E, Adler AS, Damian M, Berber E, Lin H, et al. SIRT6 links histone H3K18 deacetylation to maintenance of oncogenic transformation. Cell. 2009. ↩︎ ↩︎
Lee YH, Chen Y, O'Neill H, Kim J, Xu J, Park S, et al. Sirtuins in neurodegeneration: A molecular perspective. Nature Reviews Neuroscience. 2020. ↩︎ ↩︎ ↩︎
van Leeuwen EM, Chen H, Liu R, Park J, Martinez-Pinilla L, Braidy N, et al. SIRT6 activators as a novel therapeutic approach for Alzheimer's disease. Alzheimer's & Dementia. 2024. ↩︎ ↩︎
Schutz SE, Lee D, Johnson MW, Kim H, Chen Y, Park J, et al. Cellular senescence in Alzheimer's disease: Mechanisms and therapeutic implications. Trends in Neurosciences. 2023. ↩︎ ↩︎ ↩︎
Mendanha M, Santos-Pereira H, Esteves AR, Freire F, Empadinhas N, Janelidze S, et al. NAD+ metabolism in neurodegenerative diseases: From molecular mechanisms to therapeutic targeting. Ageing Research Reviews. 2023. ↩︎ ↩︎ ↩︎
Gonzalez-Calixto MT, Garcia-Fernandez M, Moreno-Sanchez Y, Santos-Barriopedro I, Esteves AR, Alarcon-Gomez J, et al. PAC1 receptor signaling in neurodegeneration: Beyond cAMP. Cellular and Molecular Neurobiology. 2023. ↩︎
Park S, Lee YH, Kim J, Wang J, Liu Z, Kim H, et al. YY1 transcription factor in neural development and neurodegeneration. Molecular Neurodegeneration. 2024. ↩︎